Recommendations for generating, evaluating, and implementing drug-drug interaction evidence

Pharmacotherapy

Volumn 32, Issue 4, 2012, Pages 304-313

  Hines, Lisa E ^a   Malone, Daniel C ^b   Murphy, John E ^b  

^a Pharmaco Economic Research   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Adverse drug reaction.; Clinical decision support; Drug information; Drug interaction; Drug safety; Evidence based medicine; Literature evaluation; Patient safety

Indexed keywords

ADVERSE DRUG REACTION; COMORBIDITY; CONFERENCE PAPER; DECISION SUPPORT SYSTEM; DISEASE SEVERITY; DRUG INFORMATION; DRUG INTERACTION; EVIDENCE BASED MEDICINE; HIGH RISK POPULATION; HUMAN; INCIDENCE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT SAFETY; PRACTICE GUIDELINE; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; ARTICLE; DRUG SURVEILLANCE PROGRAM; FACTUAL DATABASE; METHODOLOGY; STANDARD; TREATMENT OUTCOME;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATABASES, FACTUAL; DECISION SUPPORT SYSTEMS, CLINICAL; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; GUIDELINES AS TOPIC; HUMANS; RESEARCH DESIGN; RISK FACTORS; TREATMENT OUTCOME;

EID: 84864111670     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01024.x     Document Type: Conference Paper

References (55)

1. Hines LE, Murphy JE, Grizzle AJ, Malone DC. Critical issues associated with drug-drug interactions: highlights of a multistakeholder conference. Am J Health Syst Pharm 2011;68:941-6.
2. Oates JA. Chapter 5. The science of drug therapy. In: Brunton LL, ed. Goodman and Gilman's the pharmacological basis of therapeutics-11th ed (2006). McGraw-Hill: Medical Publishing Division, 2006:117-36.
3. Solberg LI, Hurley JS, Roberts MH, et al. Measuring patient safety in ambulatory care: potential for identifying medical group drug-drug interaction rates using claims data. Am J Manag Care 2004;10:753-9.
4. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-The-counter medications and dietary supplements among older adults in the United States. JAMA 2008;300:2867-78.
5. Malone DC, Hutchins DS, Haupert H, et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 2005;62:1983-91.
6. Lafata JE, Schultz L, Simpkins J, et al. Potential drug-drug interactions in the outpatient setting. Med Care 2006;44:534-41.
7. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003;289:1652-8.
8. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010;340:c693.
9. Peterson JF, Bates DW. Preventable medication errors: identifying and eliminating serious drug interactions. J Am Pharm Assoc (Wash) 2001;41:159-60.
10. Glassman PA, Simon B, Belperio P, Lanto A. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 2002;40:1161-71.
11. Ko Y, Malone DC, Skrepnek GH, et al. Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. Drug Saf 2008;31:525-36.
12. Weideman RA, Bernstein IH, McKinney WP. Pharmacist recognition of potential drug interactions. Am J Health Syst Pharm 1999;56:1524-9.
13. Cavuto NJ, Woosley RL, Sale M. Pharmacies and prevention of potentially fatal drug interactions. JAMA 1996;275:1086-7.
14. Abarca J, Malone DC, Armstrong EP, et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc (2003) 2004;44:136-41.
15. Olvey EL, Clauschee S, Malone DC. Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Clin Pharmacol Ther 2010;87:48-51.
16. Hines LE, Ceron-Cabrera D, Romero K, et al. Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs. Clin Ther 2011;33:36-45.
17. Wang LM, Wong M, Lightwood JM, Cheng CM. Black box warning contraindicated comedications: concordance among three major drug interaction screening programs. Ann Pharmacother 2010;44:28-34.
18. Metzger J, Welebob E, Bates DW, Lipsitz S, Classen DC. Mixed results in the safety performance of computerized physician order entry. Health Aff 2010;29:655-63.
19. Saverno KR, Hines LE, Warholak TL, et al. Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions. J Am Med Inform Assoc 2011;18:32-7.
20. Shah NR, Seger AC, Seger DL, et al. Improving acceptance of computerized prescribing alerts in ambulatory care. J Am Med Inform Assoc 2006;13:5-11.
21. Grizzle AJ, Mahmood MH, Ko Y, et al. Reasons provided by prescribers when overriding drug-drug interaction alerts. Am J Manag Care 2007;13:573-8.
22. Murphy JE, Forrey RA, Desiraju U. Community pharmacists' responses to drug-drug interaction alerts. Am J Health Syst Pharm 2004;61:1484-7.
23. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-106.
24. Huang SM, Lesko LJ, Williams RL. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues. J Clin Pharmacol 1999;39:1006-14.
25. Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 2004;76:85-96.
26. Fischer HD, Juurlink DN, Mamdani MM, Kopp A, Laupacis A. Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. Arch Intern Med 2010;170:617-21.
27. Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther 2008;84:581-8.
28. Caccia S, Garattini S, Pasina L, Nobili A. Predicting the clinical relevance of drug interactions from pre-Approval studies. Drug Saf 2009;32:1017-39.
29. Fuhr U. Improvement in the handling of drug-drug interactions. Eur J Clin Pharmacol 2008;64:167-71.
30. Anthony M, Romero K, Malone DC, Hines LE, Higgins L, Woosley RL. Warfarin interactions with substances listed in drug information compendia and in the FDA-Approved label for warfarin sodium. Clin Pharmacol Ther 2009;86:425-9.
31. Huang SM, Strong JM, Zhang L, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 2008;48:662-70.
32. Food and Drug Administration, U.S. Department of Health and Human Services. Information for healthcare professionals on FDA's new prescribing information for drugs. Available from http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084189.htm. Accessed October 29, 2010.
33. Food and Drug Administration, U.S. Department of Health and Human Services. Indexing structured product labeling for human prescription drug and biologic products; Request for comments [Docket No. FDA-2010-N-0256]. Federal Register 2010;75:33312-3.
34. Greenberg M, Ridgely MS. Clinical decision support and malpractice risk. JAMA 2011;306:90-1.
35. Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Drug Saf 2007;30:367-73.
36. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
37. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-80.
38. Bottiger Y, Laine K, Andersson ML, et al. SFINX-A drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol 2009;65:627-33.
39. Sjoqvist F. A new classification system for drug interactions. Eur J Clin Pharmacol 1997;52:327a.
40. van Roon EN, Flikweert S, le Comte M, et al. Clinical relevance of drug-drug interactions: a structured assessment procedure. Drug Saf 2005;28:1131-9.
41. Weingart SN, Simchowitz B, Shiman L, et al. Clinicians' assessments of electronic medication safety alerts in ambulatory care. Arch Intern Med 2009;169:1627-32.
42. Weingart SN, Simchowitz B, Padolsky H, et al. An empirical model to estimate the potential impact of medication safety alerts on patient safety, health care utilization, and cost in ambulatory care. Arch Intern Med 2009;169:1465-73.
43. Boyce R, Collins C, Horn J, Kalet I. Computing with evidence Part II: an evidential approach to predicting metabolic drug-drug interactions. J Biomed Inform 2009;42:990-1003.
44. Boyce R, Collins C, Horn J, Kalet I. Computing with evidence Part I: a drug-mechanism evidence taxonomy oriented toward confidence assignment. J Biomed Inform 2009;42:979-89.
45. Paterno MD, Maviglia SM, Gorman PN, et al. Tiering drug-drug interaction alerts by severity increases compliance rates. J Am Med Inform Assoc 2009;16:40-6.
46. Humphries TL, Carroll N, Chester EA, Magid D, Rocho B. Evaluation of an electronic critical drug interaction program coupled with active pharmacist intervention. Ann Pharmacother 2007;41:1979-85.
47. Weingart SN, Seger AC, Feola N, Heffernan J, Schiff G, Isaac T. Electronic drug interaction alerts in ambulatory care: the value and acceptance of high-value alerts in US medical practices as assessed by an expert clinical panel. Drug Saf 2011;34:587-93.
48. Miller RA, Gardner RM, Johnson KB, Hripcsak G. Clinical decision support and electronic prescribing systems: a time for responsible thought and action. J Am Med Inform Assoc 2005;12:403-9.
49. Kuperman GJ, Reichley RM, Bailey TC. Using commercial knowledge bases for clinical decision support: opportunities, hurdles, and recommendations. J Am Med Inform Assoc 2006;13:369-71.
50. Horn JR, Hansten PD, Osborn JD, Wareham P, Somani S. Customizing clinical decision support to prevent excessive drug-drug interaction alerts. Am J Health Syst Pharm 2011;68:662-4.
51. van der Sijs H, van Gelder T, Vulto A, Berg M, Aarts J. Understanding handling of drug safety alerts: a simulation study. Int J Med Inform 2010;79:361-9.
52. Sittig DF, Wright A, Osheroff JA, et al. Grand challenges in clinical decision support. J Biomed Inform 2008;41:387-92.
53. Board on Health Care Services and Institute of Medicine. Chapter 6. Action agenda for the pharmaceutical, medical device, and heath information technology industries. In: Aspden P, Wolcott JA, Bootman JL, Cronenwett LR, eds. Preventing medication errors: Quality chasm series. Washington, DC: National Academies Press, 2007:266-309.
54. Hansten PD, Horn JR, Hazlet TK. ORCA: OpeRational ClassificAtion of drug interactions. J Am Pharm Assoc (Wash) 2001;41:161-5.
55. Hines LE, Saverno KR, Warholak TL, et al. Pharmacists' awareness of clinical decision support in pharmacy information systems: an exploratory evaluation. Res Social Adm Pharm 2011;7:359-68.